Cost-effectiveness of universal childhood hepatitis A vaccination in Chile

M. Teresa Valenzuela, R. Jake Jacobs*, Oscar Arteaga, Maria S. Navarrete, Allen S. Meyerhoff, Bruce L. Innis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80%. Vaccination costs of US$ 5.3-6.4 million would be offset by US$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and >4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile.

Original languageEnglish
Pages (from-to)4110-4119
Number of pages10
Issue number32
StatePublished - 14 Jul 2005

Bibliographical note

Funding Information:
We thank the following groups and individuals: the Ministry of Health, for supporting our access to data required to conduct this analysis; Dr. Betsy Hunter and Lorena Calabrán, Hospital Luis Calvo Mackenna, for providing information on children with acute liver failure; the Infectious Disease Hospital, Hospital Lucio Cóórdoba, for assisting the cost analysis of adult patients; and CVD-Chile, for assisting the cost analysis of pediatric patients. This study was supported in part by an research grant from GlaxoSmithKline Biologicals to Capitol Outcomes Research Inc. Drs. Navarrete and Innis are employees of GlaxoSmithKline.


  • Cost and cost analysis
  • Hepatitis A
  • Vaccination


Dive into the research topics of 'Cost-effectiveness of universal childhood hepatitis A vaccination in Chile'. Together they form a unique fingerprint.

Cite this